UNH UnitedHealth Group Inc

UnitedHealth Group is the largest US health insurer, operating both health benefits through UnitedHealthcare and a broad health services business through Optum. Sector: Healthcare.

UnitedHealth Group Inc (UNH) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Looking at how effectively the company deploy capital, ROIC is 7.64%, WACC is 7.91%, and the economic spread is -0.26%. On balance, capital is being deployed at rates below what debt and equity holders require, a headwind to long-term value creation if sustained. Supporting metrics show ROE at 12.31% and ROA at 3.83%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that likely needs operating improvement before returns quality can be considered durable.

On valuation, the company registers trailing P/E of 28.91, forward P/E of 20.52, PEG of 30.18. The spread between the two P/E figures is moderate, suggesting earnings are expected to improve gradually rather than accelerate sharply. The PEG ratio is elevated relative to historical norms, implying the market is paying a meaningful premium for the earnings trajectory embedded in analyst estimates. A current ratio reading of 0.80 suggests the company carries less short-term financial cushion than the broader market average. Taken together, the multiple and liquidity picture suggests a company that is priced for a constructive outcome — but where execution against earnings estimates will be the key determinant of whether that price is justified.

Across the three margin layers, gross margin sits at 18.80%, operating margin at 4.19%, and free cash flow margin at 4.37%. The company's gross margins are below average, reflecting sectors where input costs consume the majority of revenue. The company's operating margins are minimal, reflecting a company where overhead costs are not yet well absorbed by revenues. At this level, free cash flow is not a meaningful source of financial flexibility for the company's underlying the company. This margin configuration supports a cautious interpretation: profitability exists, though durability is less certain under stress.

Two key indicators frame the near-term view: TTM revenue growth of 1.96% indicating muted but still positive top-line momentum across the company, while the estimated 12-month price change of 20.75%, where the target distribution indicates incremental upside rather than outsized repricing. The near-term return case is built on whether reported trends and analyst projections can remain close enough to make current prices look justified. Whether the setup resolves positively or negatively will depend as much on the macro backdrop as on the capacity of the company to deliver against current estimates. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Taken together, the signals neither mandate urgency nor raise serious alarm — the profile warrants monitoring as the picture evolves.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.